Pain Therapeutics (PTIE) Earns Daily Media Sentiment Rating of 0.11
Media coverage about Pain Therapeutics (NASDAQ:PTIE) has trended somewhat positive this week, Accern Sentiment Analysis reports. The research group scores the sentiment of media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Pain Therapeutics earned a news impact score of 0.11 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 46.8404527192302 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
These are some of the headlines that may have impacted Accern’s analysis:
- Pain Therapeutics (PTIE) Downgraded by ValuEngine (americanbankingnews.com)
- Pain Therapeutics, Inc. (PTIE) : Analysts Watch-List Stock – Wall Street Morning (wallstreetmorning.com)
- Pain Therapeutics (PTIE) REMOXY NDA Accepted by FDA, Sets August 7 PDUFA Date – StreetInsider.com (streetinsider.com)
- How Should You Think About Pain Therapeutics Inc’s (NASDAQ:PTIE) Risks? (finance.yahoo.com)
Shares of Pain Therapeutics (NASDAQ PTIE) traded down $0.27 during midday trading on Monday, hitting $7.17. 89,916 shares of the company traded hands, compared to its average volume of 955,828. Pain Therapeutics has a 12 month low of $3.10 and a 12 month high of $12.80. The stock has a market capitalization of $48.15, a P/E ratio of -3.95 and a beta of 2.77.
Several research analysts recently commented on PTIE shares. ValuEngine downgraded shares of Pain Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, December 1st. Zacks Investment Research downgraded shares of Pain Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, February 24th.
About Pain Therapeutics
Pain Therapeutics, Inc is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company’s lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company’s other products is FENROCK.
Receive News & Ratings for Pain Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pain Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.